RecruitingNCT06634641

Clozapine-related Immunodeficiency in Parkinsons Disease

Interventional studyAges 18+FranceSchizophrenia

The study in practice

Understand this study

Listed age limits: from 18 years.

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Study start dateStarted: October 1, 2024

Recruitment status: Recruiting
Enrollment listed in the registry: 24
Sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor type: Unknown or unclear
Study type: Biological
Intervention type: BIOLOGICAL
Study phase: Phase 4
Locations: France
Age range: Over 18 Years
Official registry ID: NCT06634641
Official title: Show the full official title
Assessment of Clozapine-related Immunodeficiency Effect in Parkinsons Disease Patients

Leave your email and we’ll get in touch to discuss your questions and possible next steps.

Recruiting

Salouël

A listed location does not confirm current availability.

FAQ

Who is behind this study?

The study sponsor is Centre Hospitalier Universitaire, Amiens.

Who can participate?

Listed age limits: from 18 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.